B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels,disease measures and time

Abstract

Overexpression of B-lymphocyte activating factor (BAFF) results in arthritis, glomerulonephritis and autoantibody formation in mice, but its role in human autoimmune disease is less obvious. Serum BAFF levels in patients with systemic lupus erythematosus (SLE) (n = 42) and rheumatoid arthritis (RA) (n = 60) were related to levels of disease activity, anti-dsDNA Ab, anti-ENA Ab, rheumatoid factor (RF) and anti-CCP Ab. BAFF levels were also followed over time in 19 SLE patients. BAFF levels correlated inversely with age, were higher in SLE than RA (median 2.7 versus 1.4 ng/mL, P < 0.01) and more SLE than RA patients had increased BAFF levels (57% versus 10%, P ≤ 0.01). In SLE, BAFF levels correlated with SLEDAI scores but not with anti-dsDNA Ab levels. SLE patients with increased BAFF levels had higher SLEDAI and CRP levels. In RA, BAFF levels correlated weakly with anti-CCP levels (Rs 0.27, P = 0.07), but not with joint counts, ESR, CRP or RF levels. Longitudinal BAFF levels remained unaltered in two thirds of SLE patients and changes in BAFF levels were unrelated to disease flares. These findings suggest that BAFF stimulation of B-cells may contribute to SLE by other mechanisms than autoantibody production.

Keywords

autoantibodies B-cell activating factor rheumatoid arthritis systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Illei GG , Lipsky PE. Biomarkers in systemic lupus erythematosus . Curr Rheumatol Rep 2004; 6: 382-390 .

Sims GP , Ettinger R , Shirota Y , Yarboro CH , Illei GG , Lipsky PE. Identification and characterization of circulating human transitional B cells . Blood 2005.

Moore PA , Belvedere O , Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator . Science 1999; 285: 260-263 .

Schneider P , Mackay F , Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth . J Exp Med 1999; 189: 1747-1756 .

Do RK , Hatada E , Lee H , Tourigny MR , Hilbert D , Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response . J Exp Med 2000; 192: 953-964 .

Avery DT , Kalled SL , Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells . J Clin Invest 2003; 112: 286-297 .

Stohl W. SLE - systemic lupus erythematosus: a BLySful, yet BAFFling, disorder . Arthritis Res Ther 2003; 5: 136-138 .

Gross JA , Johnston J , Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease . Nature 2000; 404: 995-999 .

Gross JA , Dillon SR , Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS . Immunity 2001; 15: 289-302 .

10.

Mackay F , Woodcock SA , Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations . J Exp Med 19996; 190: 1697-1710 .

11.

Mackay F , Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity . Trends Immunol 2002; 23: 113-115 .

12.

Nikolaisen C , Rekvig OP , Nossent HC. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis . Scand J Rheumatol 2005; 34: 269-276 .

13.

Nossent HC. Systemic lupus erythematosus in the Arctic region of Norway . J Rheumatol 2001; 28: 539-546 .

14.

Olaussen E , Rekvig OP. Screening tests for antinuclear antibodies (ANA): selective use of central nuclear antigens as a rational basis for screening by ELISA . J Autoimmun 1999; 13: 95-102 .

15.

Rekvig OP , Andreassen K , Moens U. Antibodies to DNA - towards an understanding of their origin and pathophysiological impact in systemic lupus erythematosus . Scand J Rheumatol 1998; 27: 1-6 .

16.

Hernando M , Gonzalez C , Sanchez A et al. Clinical evaluation of a new automated anti-dsDNA fluorescent immunoassay . Clin Chem Lab Med 2002; 40: 1056-1060 .

17.

Lopez-Hoyos M , Cabeza R , Martinez-Taboada VM et al. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus . Lupus 2005; 14: 505-509 .

18.

Bertolaccini ML , Hughes GR , Khamashta MA. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins . Clin Lab 2004; 50: 653-665 .

19.

Schellekens GA , Visser H , de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide . Arthritis Rheum 2000; 43: 155-163 .

20.

Stohl W , Metyas S , Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations . Arthritis Rheum 2003; 48: 3475-3486 .

21.

Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases . Curr Rheumatol Rep 2002; 4: 345-350 .

22.

Cheema GS , Roschke V , Hilbert DM , Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases . Arthritis Rheum 2001; 44: 1313-1319 .

23.

Pers JO , Daridon C , Devauchelle V et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases . Ann N Y Acad Sci 2005; 1050: 34-39 .

24.

Matsushita T , Hasegawa M , Yanaba K , Kodera M , Takehara K , Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes . Arthritis Rheum 2006; 54: 192-201 .

25.

Youinou P , Jamin C , Pers JO , Berthou C , Saraux A , Renaudineau Y. B lymphocytes are required for development and treatment of autoimmune diseases . Ann N Y Acad Sci 2005; 1050: 19-33 .

26.

Kalled SL. The role of BAFF in immune function and implications for autoimmunity . Immunol Rev 2005; 204: 43-54 .

27.

Rekvig OP , Nossent JC.

Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms?

Arthritis Rheum 2003; 48: 300-312 .

28.

Novak AJ , Darce JR , Arendt BK et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival . Blood 2004; 103: 689-694 .

29.

Ramanujam M , Wang X , Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE . J Clin Invest 2006; 116: 724-734 .

30.

Kawasaki A , Tsuchiya N , Fukazawa T , Hashimoto H , Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis . Genes Immun 2002; 3: 424-429 .

31.

Gottenberg JE , Sellam J , Ittah M et al. No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjogren’s syndrome . Arthritis Res Ther 2006; 8: R30-R30 .

32.

Szodoray P , Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren’s syndrome . Scand J Immunol 2005; 62: 421-428 .

33.

Mariette X. [ Pathophysiology of Sjogren’s syndrome] . Ann Med Interne (Paris) 2003; 154: 157-168 .

34.

Mariette X , Roux S , Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome . Ann Rheum Dis 2003; 62: 168-171 .

35.

Min H , Montecino-Rodriguez E , Dorshkind K. Effects of aging on the common lymphoid progenitor to pro-B cell transition . J Immunol 2006; 176: 1007-1012 .

36.

Allman D , Miller JP. B cell development and receptor diversity during aging . Curr Opin Immunol 2005; 17: 463-467 .